|
|
Sleepiness is one of
the best known symptoms of infectious diseases. Hence one
might hypothesize some relationship between the regulation
of sleep and the body’s immune response to infection.
Some scientists believe that certain hypnogenic peptides
might cause fevers and mobilize the body’s immune response.
For example, cytokines, whose production
is stimulated by infections, may cause an increase in sleep
and thus help to increase the body’s immune defences.
Interleukin-1 is
an example of these peptides that simultaneously stimulate
the immune system and promote sleep. This peptide is synthesized
in the glial
cells of the brain and in the macrophages that remove
foreign bodies from the organism.
|
|
|
| MOLECULES THAT BUILD
UP AND MAKE YOU SLEEP |
|
The onset of sleep is triggered not
only by your body’s
biological clock, which regulates the cyclical
secretion of hormones determining the best time to go to sleep,
but also by the cumulative effect of hypnogenic molecules that
build up in the body while you are awake.
The molecule adenosine has a number of characteristics
that make it an ideal candidate to act as one of these hypnogenic
substances: its concentration in the brain is higher during waking
periods than during sleep and increases during extended periods
of wakefulness; moreover, administering adenosine or its agonists
to experimental subjects makes them sleepy.
Adenosine is produced by the degradation of adenosine triphosphate
(ATP), the molecule that serves as the “energy currency” for
the body’s various cellular functions. The amount of adenosine
produced in the brain thus reflects the activity level of its neurons and glial
cells. The brain’s intense activity during periods of
wakefulness consumes large amounts of ATP and hence causes adenosine
to accumulate.
The accumulation of adenosine during waking periods is thus
associated with the depletion of the ATP reserves stored
as glycogen in the brain. The increased adenosine levels
trigger non-REM sleep, during which the brain is less active,
thus placing it in a recovery phase that is absolutely essential—among
other things, to let it rebuild its stores of glycogen.
Because adenosine is continuously metabolized by the enzyme adenosine
desaminase, the decline in adenosine production during
sleep quickly causes a general decline in adenosine concentrations
in the brain, eventually producing conditions more favourable
to awakening.
Some interesting experimental results have been obtained when
rats were injected with adenosine agonists that are not broken
down by adenosine desaminase. These substances increased the amount
of non-REM sleep, but decreased the amount of REM sleep, during
which the brain is very active. But because REM sleep normally
represents only 15% of the time that rats are asleep, these substances
also significantly increased the total amount of time that the
rats slept.
Similar results were also obtained with the administration of
an adenosine desaminase inhibitor, which reduced the efficiency
with which adenosine was metabolized and hence increased its concentration
in the brain.
One of the first explanations proposed for the mechanisms by which
adenosine exerts its hypnogenic effect was as follows. The binding
of adenosine molecules to their receptors inhibits the enzyme adenylate
cyclase, thus suppressing the inflow of calcium ions into the presynaptic
terminals. And because this inflow normally promotes the release
of neurotransmitters, smaller amounts of neurotransmitters would
then be secreted by many neurons associated with wakefulness, such
as those in the basal
telencephalon. And that is how adenosine would exert its hypnogenic
effect.
But what about those parts of the brain that
were known to contain neurons whose stimulation promotes sleep,
such as the preoptic
anterior hypothalamus? Researchers soon found that injecting
microscopic amounts of adenosine into these parts of the brain
promoted sleep too. But according to the hypothesis described in
the preceding paragraph, this result was paradoxical: reducing
the activity of neurons that promote sleep should have promoted
wakefulness instead.
| What these researchers had failed to
consider was the tremendously complex interplay of the various
subtypes of adenosine receptors, which often have opposing
effects. Subsequent research has shown that there are at least
two different subtypes of adenosine receptors, with opposite
effects: A1 receptors, which are inhibitory,
and A2A receptors, which are excitatory. That
is why adenosine can simultaneously have inhibitory effects
via the A1 receptors on neurons that are active during wakefulness,
such as those of the basal telencephalon, and excitatory effects
via the A2A receptors in brain areas where neuronal activity
encourages sleep. |
|
That said, some in vitro experiments have also shown
that adenosine may act presynaptically by inhibiting some inhibitory
GABAergic inputs, possibly via the A1 adenosine receptors. In this
way, adenosine might, for example, disinhibit some neurons in the
preoptic anterior hypothalamus, thus further encouraging sleep.
Yet another example of the immensely complex potential combinations
of effects on the synapses of the brain.
|
|